Metadon Viatris

Methadone, the active ingredient in Metadon Viatris, is an opioid analgesic presented as an injectable solution for intramuscular or subcutaneous use. It is employed in the management of opioid dependence and chronic pain in adult patients.

GNH USA supplies Metadon Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metadon Viatris is an opioid agonist used in the following clinical situations:

Opioid dependence: facilitates withdrawal management and maintenance therapy. Chronic pain: provides long‑acting analgesia for severe, persistent pain. Opioid substitution therapy: maintains opioid tolerance while reducing illicit opioid use.

Methadone may cause a range of adverse reactions. Monitoring and patient education are essential.

Common Side Effects: - Nausea - Constipation - Drowsiness or sedation - Sweating - Dizziness - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - QT interval prolongation leading to arrhythmia - Severe hypotension - Seizures - Anaphylactic or severe allergic reactions - Adrenal insufficiency

When prescribing or dispensing Metadon Viatris, consider the following precautions:

Assess respiratory function: evaluate baseline breathing status before initiation. Monitor cardiac status: obtain baseline ECG to assess QT interval. Avoid abrupt discontinuation: taper dose under medical supervision to prevent withdrawal. Use cautiously in hepatic impairment: dose reduction may be required. Pregnancy considerations: Category C; weigh maternal benefits against fetal risks. Store at room temperature: keep in original container, protect from moisture and light.

Methadone can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - CYP3A4 inhibitors: may raise methadone plasma concentrations. - Concomitant CNS depressants (e.g., benzodiazepines, barbiturates): increase risk of respiratory depression. - QT‑prolonging agents: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce methadone effectiveness. - Other opioids: may require dose adjustments to avoid additive effects. - Selective serotonin reuptake inhibitors (SSRIs): potential for serotonin syndrome.